Adalimumab-Induced Acute Myelogenic Leukemia

    loading  Checking for direct PDF access through Ovid



Newer biological treatment strategies have been developed in the last decade with some promising outcomes. Their safety, however, has been questioned lately with multiple reports of increased risk for malignancies and infectious complications. These reports render their use suboptimal. We report a 44-year-old woman receiving adalimumab (Humira®) for advanced juvenile rheumatoid arthritis who then developed acute myelogenic leukemia.

Related Topics

    loading  Loading Related Articles